Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
featured
Hepatic Impairment/Liver Disease (Severe)

Single-Dose Study to Evaluate the Pharmacokinetics in Subjects with Normal and Impaired Hepatic Function.

  • 9 views
  • 25 Jan, 2021
  • 1 location
featured
A Research Study For People With Painful Diabetic Peripheral Neuropathy (DPN) is Now Enrolling

A Research Study For People With Painful Diabetic Peripheral Neuropathy (DPN) is Now Enrolling

  • 738 views
  • 25 Mar, 2021
  • 1 location
Surufatinib Hepatic Impairment Study

An open-label, multicenter, single-dose, single-period, sequential study to determine the effect of hepatic impairment on the PK of surufatinib.

  • 0 views
  • 01 Jun, 2021
  • 2 locations
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

This is a study to characterize the pharmacokinetics, safety and tolerability of KD025 and KD025 metabolites in subjects with mild, moderate or severe hepatic impairment compared to healthy

ct scan
diabetes
medication regimen
bilateral oophorectomy
prothrombin
  • 50 views
  • 04 Aug, 2021
  • 3 locations
A Study of JNJ-53718678 in Participants With Hepatic Impairment

The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild, moderate, and severe) when compared with participants with normal hepatic function.

drug tests
jnj-53718678
beta human chorionic gonadotropin
  • 0 views
  • 22 Apr, 2021
  • 2 locations
Hepatic Impairment Study for Lorlatinib in Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide

  • 0 views
  • 25 May, 2021
  • 19 locations
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in participants with moderate or severe hepatic impairment compared to

  • 0 views
  • 14 Jul, 2021
  • 5 locations
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild or moderate hepatic impairment (HI) compared to the matched control subjects

  • 0 views
  • 22 Jun, 2021
  • 1 location
Hepatic Impairment Cholestatic Liver Disease & NASH With Advanced Fibrosis & Normal Hepatic Function

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

varices
electrocardiogram
saroglitazar
body mass index
encephalopathy
  • 0 views
  • 05 Aug, 2021
  • 2 locations
A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

The purpose of this study is to compare the pharmacokinetics (PK) of MK-8189 in participants with moderate hepatic impairment (based on the Child-Pugh classification) to healthy participants

  • 0 views
  • 22 Jun, 2021
  • 2 locations